Phase 2 Readout
TLSA: Phase 2 Readout: intranasal foralumab
September 30, 2026 · intranasal foralumab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- Tiziana Life Sciences Ltd (TLSA)
- Drug
- intranasal foralumab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: intranasal foralumab
- Drug
- intranasal foralumab
- Indication
- Secondary Progressive Multiple Sclerosis